依托泊苷联合阿糖胞苷和培非格司亭用于动员不佳的多发性骨髓瘤和淋巴瘤患者:一项前瞻性多中心研究
这项在中国八家公立医院开展的单臂前瞻性临床试验纳入58例动员不佳的多发性骨髓瘤或淋巴瘤患者,评估依托泊苷、阿糖胞苷联合培非格司亭(EAP)方案的疗效与安全性。53例(91.4%)达到充分动员,41例(70.7%)达到最佳动员,中位累计采集CD34+细胞数为9.2(范围2.1-92.7)×10^6/kg。作者认为EAP动员方案可能是动员不佳的MM或淋巴瘤患者一个有前景的选择。
要点
- EAP方案后53例(91.4%)达到充分动员(≥2.0×10^6 CD34+细胞/kg)。
- 41例(70.7%)达到最佳动员,中位累计采集CD34+细胞9.2(范围2.1-92.7)×10^6/kg。
- 12例(20.7%)发生2-3级感染,25例(43.1%)需输注血小板。
核心结论
- 作者认为EAP动员方案可能是动员不佳的多发性骨髓瘤或淋巴瘤患者一个有前景的选择。
研究设计与样本
- 单臂前瞻性临床试验,在中国八家公立医院开展,注册号NCT05510089。
- 纳入标准为诊断为多发性骨髓瘤或淋巴瘤、定义为动员不佳、年龄18-75岁。
- 2022年9月1日至2023年8月15日共入组58例患者。
- EAP方案为依托泊苷75 mg/m²/天第1-2天,阿糖胞苷300 mg/m²每12小时第1-2天,培非格司亭6 mg第6天。
- 主要终点为达到充分动员(≥2.0×10^6 CD34+细胞/kg)的患者比例。
主要发现
- 53例(91.4%)达到充分动员,41例(70.7%)达到最佳动员。
- 中位累计采集CD34+细胞数为9.2(范围2.1-92.7)×10^6/kg,中位每位患者采集次数为1.2次。
- 从给予EAP方案至首次采集的中位时间为12天。
- 约8.6%的患者需要普乐沙福挽救,且均成功。
- 58例中12例(20.7%)发生2-3级感染,25例(43.1%)需输注血小板;中性粒细胞和血小板植入时间均为11天。
关键数值与推荐
- 充分动员定义为≥2.0×10^6 CD34+细胞/kg。
- EAP方案剂量:依托泊苷75 mg/m²/天第1-2天,阿糖胞苷300 mg/m²每12小时第1-2天,培非格司亭6 mg第6天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A chemotherapy-based mobilization regimen in patients who mobilize poorly, based on etoposide, cytarabine and pegfilgrastim (EAP), has recently been introduced. The aim of this prospective study was to investigate the efficacy and safety of the EAP regimen in patients with poorly mobilizing multiple myeloma (MM) or lymphoma. This single-arm clinical trial was performed at eight public hospitals in China and was registered as a clinical trial (NCT05510089). The inclusion criteria were; (1) diagnosis of MM or lymphoma, (2) defined as a 'poor mobilizer' and (3) aged 18-75 years. The EAP regimen consisted of etoposide 75 mg/m2/day on days 1-2, cytarabine 300 mg/m2 every 12 h on days 1-2 and pegfilgrastim 6 mg on day 6. The primary endpoint of the study was the ratio of patients achieving adequate mobilization (≥2.0 × 106 CD34+ cells/kg). From 1 September 2022 to 15 August 2023, a total of 58 patients were enrolled, 53 (91.4%) achieved adequate mobilization, while 41 (70.7%) achieved optimal mobilization with a median number of cumulative collected CD34+ cells was 9.2 (range 2.1-92.7) × 106/kg and the median number of apheresis per patient of 1.2. The median time from administration of the EAP regimen to the first apheresis was 12 days. Approximately 8.6% of patients required plerixa for rescue, which was successful. Twelve (20.7%) of the 58 patients suffered grade 2-3 infections, while 25 (43.1%) required platelet transfusions. The duration of neutrophil and platelet engraftment was 11 days. In conclusion, these results suggest that the EAP mobilization regimen might be a promising option for poorly mobilizing patients with MM or lymphoma.
引用
- Ye P, Cheng Y, Lian J, et al. Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study. Br J Haematol. 2024. PMID: 38400570. doi:10.1111/bjh.19367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。